Core Viewpoint - Bausch + Lomb Corporation has successfully closed a credit agreement refinancing, entering into a fourth amendment to its existing credit agreement, which includes a new tranche of term B loans totaling $2,802,125,000 to refinance existing loans due in 2028 and 2031 [1] Group 1: Credit Agreement Details - The new Replacement Term Loans have an amortization rate of 1.00% per annum, with the first installment due on June 30, 2026 [2] - The applicable margin for the Replacement Term Loans is set at 3.75% per annum for loans tied to term SOFR and 2.75% per annum for those tied to the alternate base rate, reflecting a reduction of 0.50% and 0.25% respectively from previous loans [2] - The maturity date for the Replacement Term Loans is January 15, 2031, which aligns with the maturity date of the previously existing loans, effectively extending the maturity of the First Incremental Term Loans from September 29, 2028 [2] Group 2: Company Overview - Bausch + Lomb is a leading global eye health company focused on improving vision and quality of life for individuals worldwide, with a commitment to innovation in eye care [3] - The company has a diverse product portfolio that includes contact lenses, prescription products, over-the-counter options, and surgical devices, aimed at enhancing patient outcomes [3]

Diamond Hill Capital, an investment management company, released its “Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets continued their rally in the third quarter, with US stocks gaining over 8% as measured by the Russell 3000 Index. Small-cap stocks experienced the strongest quarterly performance, rising by more than 12%, whereas large-cap stocks increased by about 8%, and mid-cap stocks saw a gain of 5%. The strategy underperformed the Russell Midca ...

Enters into Cooperation Agreement with Browning WestSAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company’s Board of Directors (the “Board”) has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the “Cooperation Agreement”) with Browning West, LP. (“Browning West”). ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zac ...

Cooper Companies (NASDAQ:COO) stock rose Friday after the company reported better-than-expected fourth-quarter earnings and upbeat financial guidance.The company also said it is conducting a formal review of the company’s portfolio, structure, strategy, operations, and capital priorities.The review aims to identify opportunities to streamline the business and unlock additional long-term value, including potential partnerships, joint ventures, divestitures, mergers, or other transactions.Also Read: Activist ...

Core Points - CooperCompanies has appointed Colleen Jay as the new Chair of the Board, effective January 2, 2026, succeeding Robert Weiss, who will remain on the Board for reelection [1][2] - The company is undergoing a formal strategic review to identify opportunities for enhancing long-term shareholder value [1][4] Leadership Changes - Colleen Jay has been on the Board since 2016 and has a strong background in global operational leadership, having retired from Procter & Gamble in 2017 after 32 years [2] - Robert Weiss has been a significant figure in CooperCompanies' success for nearly five decades, serving in various leadership roles including CEO from 2007 to 2018 [3] Strategic Review - The strategic review aims to improve performance in core markets, expand market share, enhance operational efficiency, and generate strong returns through disciplined capital deployment [4] - The company plans to focus on share repurchases under a $2 billion share repurchase program during this review period [4] Company Overview - CooperCompanies operates in the medical device sector with two main business units: CooperVision, a leader in the contact lens industry, and CooperSurgical, focused on fertility and women's healthcare [5] - The company has a workforce of over 15,000 and sells products in more than 130 countries, positively impacting over 50 million lives annually [5]

Core Insights - CooperCompanies reported strong financial results for fiscal year 2025, exceeding consensus expectations for revenue, earnings, and free cash flow, with a focus on long-term shareholder value through growth and profitability initiatives [2][5]. Financial Performance - Fourth quarter revenue reached $1,065.2 million, a 5% increase year-over-year, with organic growth of 3% [5][6]. - Fiscal year 2025 revenue totaled $4.1 billion, also up 5% from the previous year, with organic growth of 4% [5][13]. - GAAP diluted earnings per share (EPS) for Q4 was $0.43, down 27%, while fiscal year GAAP diluted EPS was $1.87, down 4% [5][27]. - Non-GAAP diluted EPS for Q4 was $1.15, up 11%, and for the fiscal year, it was $4.13, up 12% [5][27]. Segment Performance - CooperVision (CVI) revenue for Q4 was $709.6 million, a 5% increase year-over-year, with organic growth of 3% [6][59]. - CooperSurgical (CSI) revenue for Q4 was $355.6 million, up 4% year-over-year, with organic growth also at 4% [12][59]. Margins and Costs - Gross margin for Q4 was 61%, down from 67% in the previous year, primarily due to reorganization costs [6][13]. - Non-GAAP gross margin was 66%, down 70 basis points from last year [6][13]. - Operating margin for Q4 was 13%, compared to 19% in the previous year, while non-GAAP operating margin improved to 27% [6][13]. Cash Flow and Share Repurchase - Cash provided by operations was $247.8 million, leading to free cash flow of $149.8 million after capital expenditures of $98.0 million [6][13]. - The company repurchased $197.3 million of common stock in Q4 and $290.1 million for the fiscal year, with a total share repurchase authorization of $2 billion [13][14]. Future Guidance - For fiscal year 2026, the company expects total revenue between $4.299 billion and $4.338 billion, with organic growth of 4.5% to 5.5% [20]. - Non-GAAP diluted EPS guidance for fiscal 2026 is projected to be between $4.45 and $4.60 [20].

Summary of Warby Parker Conference Call Company Overview - **Company**: Warby Parker - **Industry**: Eyewear and Optical Retail - **Market Size**: Over $60 billion and growing [14] Key Points and Arguments Strategic Evolution - **Act One**: Launched as an online retailer pioneering the direct-to-consumer model, introducing concepts like home try-on and all-in pricing for glasses at $95 [4][11] - **Act Two**: Transitioned to an omnichannel retailer with over 300 stores, offering a full range of eye care services including eye exams and a growing contact lens business [5][6] - **Act Three**: Focus on AI integration in products and customer experience, with plans to launch smart glasses in partnership with Google and Samsung [6][8][17] Differentiating Factors - **Omnichannel Offering**: Warby Parker is the only eyewear retailer at scale with a true omnichannel approach, allowing customers to shop online and offline seamlessly [10] - **Value Proposition**: Maintained pricing at $95 since 2010, contrasting with competitors who raise prices annually, thus providing greater value [11][12] - **Customer Feedback Loop**: Direct-to-consumer model allows for real-time feedback and rapid product development, giving Warby Parker a competitive edge [12] Market Trends - **Post-COVID Recovery**: The optical market is returning to normal shopping behaviors, with steady demand despite some disruptions due to tariffs [15][42] - **Consumer Behavior**: Younger consumers are exhibiting smaller basket sizes, impacting sales growth, but older demographics remain stable [23][24] Growth Opportunities - **AI Glasses**: Anticipated to be a significant new business, with potential for high consumer demand and integration with existing Google and Samsung ecosystems [17][19] - **Store Expansion**: Plans to increase store count significantly, with a goal of over 900 stores, leveraging community locations to enhance accessibility [28][30] Financial Performance - **Revenue Growth**: Reported over 15% top-line growth in Q3, with a focus on customer growth as the primary driver [21][22] - **Profitability Outlook**: Maintained profitability outlook despite revenue adjustments due to changing consumer behaviors; efficiencies driven by AI integration are expected to continue [25][26] Challenges and Mitigation Strategies - **Tariffs Impact**: Successfully offset tariff impacts through production shifts, selective price increases, and cost-cutting measures [38][39] - **Insurance Adoption**: Working to increase insurance coverage acceptance, which is currently underpenetrated compared to competitors [50][51] Future Outlook - **Stable Demand**: Expectation of stable consumer demand in the next 12 months, with potential for growth driven by new product launches and market expansion [42][43] - **Capital Allocation**: Plans to explore strategic opportunities and return capital to shareholders, with a healthy balance sheet and no debt [45] Additional Insights - **AI Integration**: Significant investments in AI are expected to enhance operational efficiencies and product offerings, with a focus on maintaining gross margins in the mid-50s% [35][36][37] - **Consumer Engagement**: High customer satisfaction and engagement levels, with the highest Net Promoter Score (NPS) in the category, driving organic growth [33] This summary encapsulates the key insights and strategic directions discussed during the Warby Parker conference call, highlighting the company's innovative approach and market positioning within the eyewear industry.

SINGAPORE, Dec. 1, 2025 /PRNewswire/ -- CooperVision Asia Pacific, in collaboration with CEVA Logistics, has opened a new Regional Service Centre in Singapore, marking a significant milestone in both companies’ commitment to enhance supply chain and logistics capabilities across the Asia Pacific region. Strategically located in CEVA’s healthcare hub facility within Singapore’s Airport Logistics Park, a designated free trade zone adjacent to Changi Airport, the centre marks the first phase of a broader infra ...

Company Overview - The Cooper Companies, Inc. (COO) has a market cap of $14.4 billion and operates globally in the medical device sector, focusing on contact lenses through CooperVision and women's and family health care products via CooperSurgical [1] Stock Performance - COO shares have underperformed the broader market over the past 52 weeks, declining 27.4% while the S&P 500 Index gained 12.3% [2] - Year-to-date, COO shares have decreased by 21.5%, compared to a 12.5% return for the S&P 500 [2] Financial Performance - In Q3 2025, COO reported adjusted EPS of $1.10, which was stronger than expected, but shares fell 12.9% the following day due to missed revenue estimates of $1.06 billion [4] - The company revised its full-year revenue guidance down to $4.07 billion - $4.10 billion, citing a significant drop in contact lens demand in Asia, particularly China, and a slowdown in the U.S. market [4] Analyst Expectations - For the fiscal year ending in October 2025, analysts project a 10.8% year-over-year growth in adjusted EPS to $4.09 [5] - The consensus rating among 17 analysts is a "Moderate Buy," with nine "Strong Buy" ratings, one "Moderate Buy," six "Holds," and one "Strong Sell" [5] Analyst Ratings and Price Targets - The current analyst configuration is slightly less bullish than three months ago, with 10 "Strong Buy" ratings previously [6] - Wells Fargo analyst downgraded COO to "Hold" with a price target of $72, while the mean price target of $81.88 suggests a 13.4% premium to the current price [6] - The highest price target of $96 indicates a potential upside of nearly 33% [6]